CN103421831B - For improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human - Google Patents
For improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human Download PDFInfo
- Publication number
- CN103421831B CN103421831B CN201310282063.6A CN201310282063A CN103421831B CN 103421831 B CN103421831 B CN 103421831B CN 201310282063 A CN201310282063 A CN 201310282063A CN 103421831 B CN103421831 B CN 103421831B
- Authority
- CN
- China
- Prior art keywords
- expression vector
- sequence
- leu
- gene
- pci
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses a kind of for improving the mosaic gene and construction process thereof that the hepatocellular physiological CYP3A4 of vitro culture of human expresses; Described mosaic gene, comprises the activation domain sequence of people's nf Pregnane X Receptor full length gene sequence and wild type P53 gene.Also has a kind of recombinant eukaryon expression vector, it mosaic gene described before comprising; A kind of construction process of foregoing recombinant eukaryon expression vector, wherein, it comprises the following steps: the activation domain sequence of cloning described people's nf Pregnane X Receptor full length gene sequence and wild type P53 gene from the cDNA in normal people's primary hepatocyte source respectively; Two sections of sequence directed clonings abovementioned steps obtained, between the β-globin/IgG chimeric intron sequence and SV40Late poly (A) signal sequence of described PCI-neo mammalian expression vector, obtain recombinant eukaryon expression vector.The present invention can significantly improve the hepatocellular physiological CYP3A4 of vitro culture of human and express.
Description
Technical field
The present invention relates to a kind of construction of eukaryotic expression vector technology, particularly relating to a kind of for improving the mosaic gene and construction process thereof that the hepatocellular physiological CYP3A4 of vitro culture of human expresses.
Background technology
Major part medicine enters the metabolic process after in body and completes primarily of liver cell.Liver cell contains the enzyme of various participation inside and outsides material bio-transformation.Cytochrome P 450 enzymes (CYPs, P450s) is the monooxygenase superfamily protein of a class containing hemochrome sulfhydryl structure, has been the important drugs metabolic enzyme of the detoxification/bioactivation of related substrates.Wherein, CYP3A subfamily content in human liver organization is the highest, accounts for 30%, is main clinical medicine metabolic enzymes.CYP3A4 take part in the metabolic process of the clinical application of 50%, and drug metabolism spectrum widely.In view of the vital role of CYP3A4 in drug metabolism processes, drug development process needs one can reproduce the metabolic external model of CYP3A4 in body, be used for concentrating and evaluate CYP3A4 to drug candidate metabolism and level, and drug candidate is on the impact of CYP3A4 active function.
Primary human liver cell is best suited for the CYP3A4 In vitro cell model for drug metabolism, its expressed intact I phase, II phase metabolic enzyme and other participate in molecule, can the metabolism of aids drug in human body more exactly, be the gold standard of external drug metabolism.In primary human liver cell, the substance of CYP3A4 expression and regulation mechanism is as follows: nf Pregnane X Receptor (PXR) is the most important transcription factor that regulation and control CYP3A4 transcribes, PXR and retinoic acid receptor X (RXR) α forms heterodimer, combine with the element such as nearly Pregnane X Receptor response element (prPXRE) and exogenous increased response module (XREM), the physiological of regulation and control CYP3A4 expresses (constitutive character and inducibility).
But due to primary human liver cell source shortage, difference in crowds is large, and cultured cell in vitro phenotype maintains the shortcomings such as difficulty, therefore the primary human liver cell of widespread use is more difficult.By contrast, hepatoma cell line then do not exist primary hepatocyte limited source, vitro culture difficulty etc. shortcoming, they have in-vitro multiplication ability, heredity and function phenotype relatively stable, and culture condition fairly simple and be easy to laboratory monitoring seek unity of standard.The method mainly transfection codes for tumor virogene of primary hepatocyte immortalization, the plasmid of proto-oncogene or Telomerase.Along with progress of research, the clone having occurred hybrid cell, Conditional immortalization liver cell and be separated from transgenic animal.But after primary hepatocyte immortalization, cell phenotype changes, particularly CYP3A4 expresses low, so and be not suitable for CYP3A4 related drugs metabolism research.
Liver source sexual cell is ubiquitous subject matter, is in and dedifferentes or low differentiation state, and all kinds of metabolic enzyme expression level lowly or incomplete.Therefore, the core objective of relevant transformation concentrates on how to recover and improve liver feature functionality phenotype.The method of another kind of engineered cells function is, by the plasmid of transfection coding CYP3A4, process LAN CYP3A4 in clone, improves the application potential quality of clone in the metabolism of CYP3A4 related drugs.Various non-liver sources property host cell is as bacterium, and yeast, insect cell, mammalian cell etc., by successful modification.1991, bibliographical information is successful expression in bone-marrow-derived lymphocyte sample stem cell.1998, Chen Q et al success expressed CYP3A4 in CHL cells, and for aflatoxin B1, the metabolism research of endoxan and sterigmatocystin.Hep G2 is as most widely used hepatoma cell line, and lot of documents is reported in successful process LAN CYP3A4 in Hep G2, and for the relevant drug metabolism of CYP3A4 and toxicity research.But the reforming mode of this process LAN CYP3A4 can not reproduce the physiological reaction characteristics of drug metabolism enzyme, the major issue predicting the clinical drug therapies such as drug interaction therefore can not be used for.
For realizing the object of simulation physiological regulation, people to conduct in-depth analysis research to CYP3A4 expression and regulation mechanism.Contrast the related gene expression of primary human liver cell, regulation and control and enzymic activity basic parameter, CYP3A4 expresses the reduction transcription factor relevant to CYP3A4 in clone and cofactor expression minimizing has Close relation to have scholar to find.If Hep G2 is compared with primary hepatocyte, 15%, the HNF3 α that C/EBP α mRNA only reaches primary hepatocyte is 25%, HNF1 α is 40%.Have scholar by the plasmid of the encode specialized transcription factor of transfection (C/EBP α, HNF3 γ, PXR), success improves the expression of CYP3A4 at Hep G2.Jenni K ü blbeck et al.(2010) transform out a kind of chimeric transcription factor, the P65 activation domain by NF-κ B is connected to PXR and forms mosaic gene, and transformation C3A cell, improves the expression of its CYP3A4.Although process LAN associated transcription factor can strengthen the expression of CYP3A4, still do not reach the expression level of primary hepatocyte far away.Because CYP3A4 is the regulated and control network of the complexity that a multiplefactor participates at intracellular expression regulation, expression that is single or several transcription factors improves, the expression of CYP3A4 can not be made to return to normal level, so still need to do CYP3A4 expression regulation further to attempt research.
P53 gene, the P53 albumen of its coding is core tumor suppression phosphorylated protein, and coerce when cell meets with in normal cell, when especially cell DNA sustains damage, P53 albumen sharply increases, and is mainly used in arresting cell cycle or cell death inducing; Once P53 gene is undergone mutation, P53 protein inactivation, cell fission loses restraining, may cause canceration.Half is about had to be to undergo mutation inactivation due to this gene in human cancer.P53 albumen comprise activation domain (TAD) that 4 function point analysis region: N-hold, DNA binding domain (DBD), C-end reset regulate territory and four multimerisation domain (4D), wherein the dynamic change of the activation domain (P53-AD) of the N-end of P53 albumen imparts the multifunctionality in this region.
There is some corners and spiral in P53-AD, these corners and spiral are generally the binding site of P53 albumen and other albumen (as mdm2) or chaperone, and the position of these corners and spiral and quantity can also change to some extent, which imply P53 albumen can combine with multiple protein companion thus perform various kinds of cell regulatory function.Researchist has found the protein (IUP) of its inside non-structured in P53-AD, IUP can be combined with other chaperones by changing himself structure, the IUP of this P53-AD has similar structure to other activation domains of albumen many, namely may the multi-functional, hydrophobic zonule of basis of formation structural motif, which imply P53-AD has similar structure and corresponding function to other transcription activating domain or transcription factor.P53 gene is tumor suppressor gene, it plays a significant role in cell cycle regulating, and phosphorylation has played most important functions in the Active Regulation of P53 albumen, can be controlled by the activity of phosphorylation degree to P53-AD of part important amino acid residue in control P53-AD.
Summary of the invention
The object of the invention is, with regulatory mechanism in CYP3A4 cell and based on the theoretical investigation of the above function about P53-AD for theoretical basis, according to PXR and P53 protein structure feature, P53-AD is selected to build the mosaic gene meeting the expectation of contriver's technology, the mosaic gene namely providing a kind of physiological CYP3A4 for improving Cultured Hepatocytes in vitro to express and construction process thereof.
For reaching above technical purpose, the technical solution used in the present invention is as follows:
For improving the mosaic gene that the hepatocellular physiological CYP3A4 of vitro culture of human expresses, wherein, its sequence is for shown in SEQ ID No.1 or SEQ ID No.3.
A kind of recombinant eukaryon expression vector, is characterized in that, its mosaic gene described before comprising.
Described carrier for expression of eukaryon is mammalian cell expression vector; Particularly, be PCI-neo mammalian expression vector.Described PCI-neo mammalian expression vector comprises β-globin/IgG chimeric intron sequence successively and SV40Late poly (A) signal sequence in the early stage enhancers/promoters sequence of human cytomegalovirus and downstream thereof.
Particularly, following restriction enzyme site is comprised between the β-globin/IgG chimeric intron sequence of described PCI-neo mammalian expression vector and SV40Late poly (A) signal sequence: Nhe I, Xho I, EcoR I, Mlu I, Xba I, Sal I, Acc I, Sma I and Not I.
A construction process for foregoing recombinant eukaryon expression vector, wherein, it comprises the following steps:
(1) the cDNA human cloning nf Pregnane X Receptor full length gene sequence that normal people's primary hepatocyte of including according to GenBank database is originated;
(2) the activation domain sequence of the cDNA sequence clone wild-type P53 gene of including according to GenBank database;
(3) two sections of sequence construct orderings that described step (1) and (2) obtain are classified as the mosaic gene shown in SEQ IDNo.1 or SEQ ID No.3, and between directed cloning to the β-globin/IgG chimeric intron sequence and SV40Late poly (A) signal sequence of PCI-neo mammalian expression vector, obtain recombinant eukaryon expression vector.
Particularly, the activation domain sequence orientation of described people's nf Pregnane X Receptor full length gene sequence and wild type P53 gene is inserted on Nhe I, the Xho I of described PCI-neo mammalian expression vector, EcoR I, Mlu I, Xba I, Sal I, Acc I, Sma I and any one restriction enzyme site of Not I.
Further, the recombinant eukaryon expression vector of described acquisition is by restriction map method and/or measure its nucleotide sequence and carry out screening and identification.
Compared with prior art, the present invention has following advantage:
(1) mosaic gene of the present invention is realized by the main upstream passages of Design & reform based on this gene physiological regulation, has the specific aim of CYP3A4 physiological ability to express;
(2) mosaic gene of the present invention is by selecting P53 gene and specific function territory segment (P53-AD) thereof, makes this mosaic gene have the ability of stronger regulation and control CYP3A4 expression.
Accompanying drawing explanation
Fig. 1 is the structural representation of mammalian expression vector PCI-neo used in the present invention.
Fig. 2 is the part-structure schematic diagram of the first recombinant eukaryon expression vector PCI-hPXR-P53 of the present invention, it illustrates the activation domain sequence connecting people's nf Pregnane X Receptor full length gene sequence and wild type P53 gene in β-globin/IgG chimeric intron sequence downstream successively.
Fig. 3 is the part-structure schematic diagram of the second recombinant eukaryon expression vector PCI-P53-hPXR of the present invention, it illustrates the activation domain sequence and people's nf Pregnane X Receptor full length gene sequence that connect wild type P53 gene in β-globin/IgG chimeric intron sequence downstream successively.
Fig. 4 is that recombinant eukaryon expression vector PCI-hPXR-P53 of the present invention and PCI-P53-hPXR transfection are to the two fluorescent reporter gene detected results to CYP3A4-XREM.luc in 293T cell.
Fig. 5 is that recombinant eukaryon expression vector PCI-hPXR-P53 of the present invention and PCI-P53-hPXR transfection are to the two fluorescent reporter gene detected results to CYP3A4-XREM.luc in C3A cell.
Fig. 6 is that recombinant eukaryon expression vector PCI-hPXR-P53 of the present invention and PCI-P53-hPXR transfection are to the CYP3A4mRNA fluorescence quantitative PCR detection result in C3A cell.
Embodiment
Below in conjunction with the drawings and specific embodiments, the present invention is described in further detail.
Embodiment 1
Build recombinant eukaryon expression vector PCI-hPXR-P53 and PCI-P53-hPXR, its step is as follows:
1. the PXR included according to GenBank database and the gene order of wild-type P53-AD, design special primer, the cDNA clone PXR adopting PCR method originate from normal people's primary hepatocyte and wild-type P53-AD gene order;
2. pass through restriction endonuclease sites, by PXR and wild-type P53-AD gene directed cloning to carrier for expression of eukaryon PCI-neo(as shown in Figure 1), adopt the method screening and identification recombinant eukaryon expression vector PCI-hPXR-P53 such as enzyme is cut, order-checking, as shown in Figure 2;
3. pass through restriction endonuclease sites, by PXR and wild-type P53-AD gene directed cloning to carrier for expression of eukaryon PCI-neo(as shown in Figure 1), adopt the method screening and identification recombinant eukaryon expression vector PCI-P53-hPXR such as enzyme is cut, order-checking, as shown in Figure 3;
Embodiment 2
Dual-luciferase reporter system is for substrate is to detect the active a kind of reporting system of Photinus pyralis LUC (fireflyluciferase) with fluorescein (luciferin).Luciferase can be oxidized to oxyluciferin by catalysis luciferin, in the process of luciferin oxidation, bioluminescence (bioluminescence) can be sent, in conjunction with ocean coelenteron luciferase reporter gene altogether, when expressing with Photinus pyralis LUC quantitate gene, ocean coelenteron luciferase is adopted to reduce the changing factor of experiment.Then Chemiluminescence Apparatus (luminometer) or liquid flashing determining instrument also can be claimed to measure the bioluminescence discharged in luciferin oxidising process by fluor tester.Fluorescein and this noclilucence system of luciferase, can detect the expression of gene extremely sensitive, efficiently.
Transcription factor is a kind of protein molecule with special construction, exerts regulatory genetic expression function, also referred to as trans-acting factor.The distinguished sequence of some transcription factor only in its target promotor is combined, these specific sequences are called as cis-acting elements, the DNA binding domain of transcription factor and cis-acting elements realize covalent attachment, thus play a part to suppress or strengthen to the expression of gene.Luciferase reporter gene experiment (luciferase assay) is the important means that the special order detected in this kind of transcription factor and its target promotor combines.Its principle is summarized as follows:
A. the reporter plasmid that the specific fragment of target promotor is inserted into luciferase expression sequence front by is built, as pGL3-basic etc.
The transcription factor expression plasmid that b. will detect and reporter plasmid cotransfection 293T cell or other relevant clone.If this transcription factor can activate target promotor, then luciferase gene will be expressed, and the expression amount of luciferase is directly proportional to the action intensity of transcription factor.
C. add specific luciferase substrate, luciferase and substrate reactions, produce fluorescence, the activity of luciferase can be measured by the intensity detecting fluorescence, thus judge whether transcription factor can have effect by target promoter fragment therewith.
Quantitative fluorescent PCR is used for the result of the two fluoroscopic examination of checking further.
Based on above principle, build the reporter plasmid CYP3A4-XREM.luc of recombinant eukaryon expression vector PCI-hPXR-P53 and PCI-P53-hPXR and the subcloning vector PCI-hPXR of contrast, its step is as follows:
1. the gene order of the CYP3A4 included according to GenBank database, design special primer, the regulating and controlling sequence gene order between the cDNA clone CYP3A4-362 to+53 parts and-7838 to-7208 adopting PCR method originate from normal people's primary hepatocyte;
2. pass through restriction endonuclease sites, by the regulating and controlling sequence directed cloning between CYP3A4-362 to+53 parts and-7838 to-7208 in carrier for expression of eukaryon PGL3-basic, adopt the method screening and identification recombinant eukaryon expression vector CYP3A4-XREM.luc such as enzyme is cut, order-checking;
3. the carrier PCI-hPXR-P53 Nhe I/BamH I enzyme built is scaled off, be connected with the Nhe I/BamH I digestion products of pcDNA3.1 (+), obtain an intermediate carrier pcDNA3.1-hPXR.Intermediate carrier obtains EcoR I restriction enzyme site.The Nhe I/EcoR I digestion products of pcDNA3.1-hPXR is connected with the Nhe I/EcoR I digestion products of PCI-neo, adopts enzyme to cut qualification subcloning vector PCI-hPXR.
The functional verification of recombinant eukaryon expression vector PCI-hPXR-P53 and PCI-P53-hPXR, its step is as follows:
1. object plasmid (PCI-hPXR-P53, PCI-P53-hPXR, PCI-hPXR or PCI-neo), reporter plasmid (CYP3A4-XREM.luc) and internal reference plasmid (TK) are pressed 46ng:140ng:14ng transient transfection 293T cell respectively.After transfection 24 hours, Rifampin group (RIF+) added the Rifampin solution of 0.2 μ L10mM, and control group (RIF-) adds 0.2 μ L DMSO, and medicine irritation, after 48 hours, carries out Dual-Luciferase detection, the results are shown in Figure 4.
2. object plasmid (PCI-hPXR-P53, PCI-P53-hPXR, PCI-hPXR or PCI-neo), reporter plasmid (CYP3A4-XREM.luc) and internal reference plasmid (TK) are pressed 46ng:140ng:14ng transient transfection C3A cell respectively.After transfection 24 hours, Rifampin group (RIF+) added the Rifampin solution of 0.2 μ L10mM, and control group (RIF-) adds 0.2 μ L DMSO, and medicine irritation, after 48 hours, carries out Dual-Luciferase detection, the results are shown in Figure 5.
3. in 24 orifice plates, by 1 × 10
5the density inoculation C3A cell of individual/ml, every hole 1ml, 37 DEG C, 5%CO
2quiescent culture in incubator, then distinguishes transfection PCI-hPXR-P53, PCI-P53-hPXR, PCI-hPXR and PCI-neo.After transfection 24 hours, Rifampin group (RIF+) added the Rifampin solution of 1 μ L10mM, and control group (RIF-) adds 1 μ L DMSO.After thing stimulates 48 hours, collecting cell carries out fluorescence quantitative PCR detection, the results are shown in Figure 6.
Please refer to Fig. 4, by plasmid PCI-PXR-P53, PCI-P53-hPXR, PCI-hPXR and PCI-neo in two fluoroscopic examination 293T cell to the effect of reporter plasmid.Rif(+) organize Average normalized luciferase activity and be respectively 464 ± 9.5,2899 ± 385,320 ± 23,254 ± 25, difference has statistical significance (P < 0.05); Rif(-) organize Average normalized uciferase activity and be respectively 344 ± 11,2560 ± 247,263 ± 22,229 ± 23, difference has statistical significance (P < 0.05).
Please refer to Fig. 5, by plasmid PCI-hPXR-P53, PCI-P53-hPXR, PCI-hPXR and PCI-neo in two fluoroscopic examination C3A cell to the effect of reporter plasmid.Rif(+) organize Average normalized uciferase activity and be respectively 6633 ± 443,20046 ± 2806,1539 ± 137,626 ± 94, difference has statistical significance (P < 0.05); Rif(-) organize Average normalized uciferase activity and be respectively 4098 ± 920,16391 ± 2412,435 ± 168,732 ± 93, difference has statistical significance (P < 0.05).
Please refer to Fig. 6, changed by fluorescence quantitative PCR detection CYP3A4mRNA at C3A cell transient transfection plasmid PCI-hPXR-P53, PCI-P53-hPXR, PCI-hPXR and PCI-neo.Rif(+) organize CYP3A4mRNA2-△ △ ct value and be respectively 9.52 ± 2.61,6.01 ± 0.27,3.82 ± 0.15,1.57 ± 0.11, difference has statistical significance (P < 0.05); Rif(-) organize CYP3A4mRNA2-△ △ ct value and be respectively 8.07 ± 0.11,6.36 ± 0.94,2.37 ± 0.22,1.02 ± 0.02, difference has statistical significance (P < 0.05).
From above result, after 293T transit cell dye PCI-hPXR-P53 and PCI-P53-hPXR, uciferase activity will apparently higher than PCI-hPXR, prove that PCI-hPXR-P53 and PCI-P53-hPXR is stronger to the activation of CYP3A4 promotor, this also points out P53-AD to play certain positive effect in this process indirectly.After adding Rifampin induction, the uciferase activity of each group all improves, and illustrates that the activation of PCI-hPXR-P53 and PCI-P53-hPXR to CYP3A4 promotor is adjustable, meets normal physiological conditions.In C3A cell, because C3A cell is tumor cell of liver source, self can express the atopen of a series of participation such as PXR CYP3A4 regulating and expressings, so the uciferase activity detected all is higher than 293T cell, but overall trend and 293T cell basically identical.By two fluoroscopic examination, from gene level prove chimeric vector PCI-hPXR-P53 and PCI-P53-hPXR can in conjunction with and activate CYP3A4 promotor.
Quantitative fluorescent PCR demonstrates the result of two fluoroscopic examination further, and after C3A cell transient transfection carrier PCI-hPXR-P53 and PCI-P53-hPXR, CYP3A4mRNA transcribes and is significantly higher than PCI-hPXR, and can be induced by Rifampin.
In sum, the mosaic gene of the activation domain sequence of the people's of comprising nf Pregnane X Receptor full length gene sequence of the present invention and wild type P53 gene and construction process thereof can significantly improve the hepatocellular physiological CYP3A4 of vitro culture of human and express.
Above-described embodiment is the present invention's preferably embodiment; but be not merely restricted to the described embodiments; change, the modification done under other any does not deviate from spirit of the present invention and principle, substitute, combine, simplify; all should be the substitute mode of equivalence, be all included within protection scope of the present invention.
SEQUENCE LISTING
<110> Zhujiang Hospital attached to Nanfang Medical Univ.
<120> is for improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human
<160>5
<210>1
<211>7016
<212>DNA
<213> artificial sequence
<220>
<221>PCI-hPXR-P53
<223> mosaic gene
<400>1
tcaatattggccattagccatattattcattggttatatagcataaatcaatattggctattggcc
attgcatacgttgtatctatatcataatatgtacatttatattggctcatgtccaatatgaccgcc
atgttggcattgattattgactagttattaatagtaatcaattacggggtcattagttcatagccc
atatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgaccc
ccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacg
tcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaag
tccgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgacctt
acgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggtt
ttggcagtacaccaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccat
tgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactg
cgatcgcccgccccgttgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcaga
gctcgtttagtgaaccgtcagatcactagaagctttattgcggtagtttatcacagttaaattgct
aacgcagtcagtgcttctgacacaacagtctcgaacttaagctgcagtgactctcttaaggtagcc
ttgcagaagttggtcgtgaggcactgggcaggtaagtatcaaggttacaagacaggtttaaggaga
ccaatagaaactgggcttgtcgagacagagaagactcttgcgtttctgataggcacctattggtct
tactgacatccactttgcctttctctccacaggtgtccactcccagttcaattacagctcttaagg
ctagagtacttaatacgactcactataggctagccaccatggaggtgagacccaaagaaagctgga
accatgctgactttgtacactgtgaggacacagagtctgttcctggaaagcccagtgtcaacgcag
atgaggaagtcggaggtccccaaatctgccgtgtatgtggggacaaggccactggctatcacttca
atgtcatgacatgtgaaggatgcaagggctttttcaggagggccatgaaacgcaacgcccggctga
ggtgccccttccggaagggcgcctgcgagatcacccggaagacccggcgacagtgccaggcctgcc
gcctgcgcaagtgcctggagagcggcatgaagaaggagatgatcatgtccgacgaggccgtggagg
agaggcgggccttgatcaagcggaagaaaagtgaacggacagggactcagccactgggagtgcagg
ggctgacagaggagcagcggatgatgatcagggagctgatggacgctcagatgaaaacctttgaca
ctaccttctcccatttcaagaatttccggctgccaggggtgcttagcagtggctgcgagttgccag
agtctctgcaggccccatcgagggaagaagctgccaagtggagccaggtccggaaagatctgtgct
ctttgaaggtctctctgcagctgcggggggaggatggcagtgtctggaactacaaacccccagccg
acagtggcgggaaagagatcttctccctgctgccccacatggctgacatgtcaacctacatgttca
aaggcatcatcagctttgccaaagtcatctcctacttcagggacttgcccatcgaggaccagatct
ccctgctgaagggggccgctttcgagctgtgtcaactgagattcaacacagtgttcaacgcggaga
ctggaacctgggagtgtggccggctgtcctactgcttggaagacactgcaggtggcttccagcaac
ttctactggagcccatgctgaaattccactacatgctgaagaagctgcagctgcatgaggaggagt
atgtgctgatgcaggccatctccctcttctccccagaccgcccaggtgtgctgcagcaccgcgtgg
tggaccagctgcaggagcaattcgccattactctgaagtcctacattgaatgcaatcggccccagc
ctgctcataggttcttgttcctgaagatcatggctatgctcaccgagctccgcagcatcaatgctc
agcacacccagcggctgctgcgcatccaggacatacacccctttgctacgcccctcatgcaggagt
tgttcggcatcacaggtagcggatccacacgataccaagctcgcgaggagccgcagtcagatccta
gcgtcgagccccctctgagtcaggaaacattttcagacctatggaaactacttcctgaaaacaacg
ttctgtcccccttgccgtcccaagcaatggatgatttgatgctgtccccggacgatattgaacaat
ggttcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctccccccgtgtaag
aattcacgcgtggtacctctagagtcgacccgggcggccgcttccctttagtgagggttaatgctt
cgagcagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaa
tgctttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaa
gttaacaacaacaattgcattcattttatgtttcaggttcagggggagatgtgggaggttttttaa
agcaagtaaaacctctacaaatgtggtaaaatccgataaggatcgatccgggctggcgtaatagcg
aagaggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggacgcgccctg
tagcggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgc
cctagcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtca
agctctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaa
acttgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgac
gttggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctc
ggtctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgat
ttaacaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttcctgatgcggtatttt
ctccttacgcatctgtgcggtatttcacaccgcatacgcggatctgcgcagcaccatggcctgaaa
taacctctgaaagaggaacttggttaggtaccttctgaggcggaaagaaccagctgtggaatgtgt
gtcagttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctca
attagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgc
atctcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgccca
gttccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcct
cggcctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagc
ttgattcttctgacacaacagtctcgaacttaaggctagagccaccatgattgaacaagatggatt
gcacgcaggttctccggccgcttgggtggagaggctattcggctatgactgggcacaacagacaat
cggctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagac
cgacctgtccggtgccctgaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgac
gggcgttccttgcgcagctgtgctcgacgttgtcactgaagcgggaagggactggctgctattggg
cgaagtgccggggcaggatctcctgtcatctcaccttgctcctgccgagaaagtatccatcatggc
tgatgcaatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcgaaaca
tcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaaga
gcatcaggggctcgcgccagccgaactgttcgccaggctcaaggcgcgcatgcccgacggcgagga
tctcgtcgtgacccatggcgatgcctgcttgccgaatatcatggtggaaaatggccgcttttctgg
attcatcgactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggctacccgtga
tattgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcc
cgattcgcagcgcatcgccttctatcgccttcttgacgagttcttctgagcgggactctggggttc
gaaatgaccgaccaagcgacgcccaacctgccatcacgatggccgcaataaaatatctttattttc
attacatctgtgtgttggttttttgtgtgaatcgatagcgataaggatccgcgtatggtgcactct
cagtacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgc
gccctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctg
catgtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcct
atttttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaa
tgtgcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagaca
ataaccctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgt
cgcccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaa
agtaaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcgg
taagatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgct
atgtggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattc
tcagaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaag
agaattatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgat
cggaggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcg
ttgggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaat
ggcaacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaat
agactggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtt
tattgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccaga
tggtaagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaa
tagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactc
atatatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttt
tgataatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtaga
aaagatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaa
accaccgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaac
tggcttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccactt
caagaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccag
tggcgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtc
gggctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagata
cctacagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggt
aagcggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatcttta
tagtcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcg
gagcctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgc
tcacatggctcgacagatct
<210>2
<211>664
<212>PRT
<213> artificial sequence
<220>
<221>PCI-hPXR-P53
<223>143-576 is hPXR, 577-584 be linker, 585-656 is P53
<400>2
Arg Pro Val Asp Ala Asn Gly Arg Xaa Ala Cys Thr Val Gly Gly Leu
5 10 15
Tyr Lys Gln Ser Ser Phe Ser Glu Pro Ser Asp His Xaa Lys Leu Tyr
20 25 30
Cys Gly Ser Leu Ser Gln Leu Asn Cys Xaa Arg Ser Gln Cys Phe Xaa
35 40 45
His Asn Ser Leu Glu Leu Lys Leu Gln Xaa Leu Ser Xaa Gly Ser Leu
50 55 60
Ala Glu Val Gly Arg Glu Ala Leu Gly Arg Xaa Val Ser Arg Leu Gln
65 70 75 80
Asp Arg Phe Lys Glu Thr Asn Arg Asn Trp Ala Cys Arg Asp Arg Glu
85 90 95
Asp Ser Cys Val Ser Asp Arg His Leu Leu Val Leu Leu Thr Ser Thr
100 105 110
Leu Pro Phe Ser Pro Gln Val Ser Thr Pro Ser Ser Ile Thr Ala Leu
115 120 125
Lys Ala Arg Val Leu Asn Thr Thr His Tyr Arg Leu Ala Thr Met Glu
130 135 140
Val Arg Pro Lys Glu Ser Trp Asn His Ala Asp Phe Val His Cys Glu
145 150 155 160
Asp Thr Glu Ser Val Pro Gly Lys Pro Ser Val Asn Ala Asp Glu Glu
165 170 175
Val Gly Gly Pro Gln Ile Cys Arg Val Cys Gly Asp Lys Ala Thr Gly
180 185 190
Tyr His Phe Asn Val Met Thr Cys Glu Gly Cys Lys Gly Phe Phe Arg
195 200 205
Arg Ala Met Lys Arg Asn Ala Arg Leu Arg Cys Pro Phe Arg Lys Gly
210 215 220
Ala Cys Glu Ile Thr Arg Lys Thr Arg Arg Gln Cys Gln Ala Cys Arg
225 230 235 240
Leu Arg Lys Cys Leu Glu Ser Gly Met Lys Lys Glu Met Ile Met Ser
245 250 255
Asp Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg Lys Lys Ser
260 265 270
Glu Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu Thr Glu Glu
275 280 285
Gln Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met Lys Thr Phe
290 295 300
Asp Thr Thr Phe Ser His Phe Lys Asn Phe Arg Leu Pro Gly Val Leu
305 310 315 320
Ser Ser Gly Cys Glu Leu Pro Glu Ser Leu Gln Ala Pro Ser Arg Glu
325 330 335
Glu Ala Ala Lys Trp Trp Ser Gln Val Arg Lys Asp Leu Cys Ser Leu
340 345 350
Lys Val Ser Leu Gln Leu Arg Gly Glu Asp Gly Ser Val Trp Asn Tyr
355 360 365
Lys Pro Pro Ala Asp Ser Gly Gly Lys Glu Ile Phe Ser Leu Leu Pro
370 375 380
His Met Ala Asp Met Ser Thr Tyr Met Phe Lys Gly Glu Ile Ile Ser
385 390 395 400
Phe Ala Lys Val Ile Ser Tyr Phe Arg Asp Leu Pro Ile Glu Asp Gln
405 410 415
Ile Ser Leu Leu Lys Gly Ala Ala Phe Glu Leu Cys Gln Leu Arg Phe
420 425 430
Asn Thr Val Phe Asn Ala Glu Thr Gly Thr Trp Glu Cys Gly Arg Leu
435 440 445
Ser Tyr Cys Leu Glu Asp Thr Ala Gly Gly Phe Gln Gln Leu Leu Leu
450 455 460
Glu Pro Met Leu Lys Phe His Tyr Met Leu Lys Lys Leu Gln Leu His
465 470 475 480
Glu Glu Glu Tyr Val Leu Met Gln Ala Ile Ser Leu Phe Ser Pro Asp
485 490 495
Arg Pro Gly Val Leu Gln His Arg Val Val Asp Gln Leu Gln Glu Gln
500 505 510
Phe Ala Ile Thr Leu Lys Ser Tyr Ile Glu Cys Asn Arg Pro Gln Pro
515 520 525
Ala His Arg Phe Leu Phe Leu Lys Ile Met Ala Met Leu Thr Glu Leu
530 535 540
Arg Ser Ile Asn Ala Gln His Thr Gln Arg Leu Leu Arg Ile Gln Asp
545 550 555 560
Ile His Pro Phe Ala Thr Pro Leu Met Gln Glu Leu Phe Gly Ile Thr
565 570 575
Gly Ser Gly Ser Thr Arg Tyr Gln Ala Arg Glu Glu Pro Gln Ser Asp
580 585 590
Pro Ser Val Glu Pro Pro Leu Ser Gln Glu Thr Phe Ser Asp Leu Trp
595 600 605
Lys Leu Leu Pro Glu Asn Asn Val Leu Ser Pro Leu Pro Ser Gln Ala
610 615 620
Met Asp Asp Leu Met Leu Ser Pro Asp Asp Ile Glu Gln Trp Phe Thr
625 630 635 640
Glu Asp Pro Gly Pro Asp Glu Ala Pro Arg Met Pro Glu Ala Ala Pro
645 650 655
Pro Val Xaa Glu Phe Thr Arg Gly
660
<210>3
<211>7013
<212>DNA
<213> artificial sequence
<220>
<221>PCI-P53-hPXR
<223> mosaic gene
<400>3
tcaatattggccattagccatattattcattggttatatagcataaatcaatattggctattggcc
attgcatacgttgtatctatatcataatatgtacatttatattggctcatgtccaatatgaccgcc
atgttggcattgattattgactagttattaatagtaatcaattacggggtcattagttcatagccc
atatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgaccc
ccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacg
tcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaag
tccgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgacctt
acgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggtt
ttggcagtacaccaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccat
tgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactg
cgatcgcccgccccgttgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcaga
gctcgtttagtgaaccgtcagatcactagaagctttattgcggtagtttatcacagttaaattgct
aacgcagtcagtgcttctgacacaacagtctcgaacttaagctgcagtgactctcttaaggtagcc
ttgcagaagttggtcgtgaggcactgggcaggtaagtatcaaggttacaagacaggtttaaggaga
ccaatagaaactgggcttgtcgagacagagaagactcttgcgtttctgataggcacctattggtct
tactgacatccactttgcctttctctccacaggtgtccactcccagttcaattacagctcttaagg
ctagagtacttaatacgactcactataggctagccaccatggaggagccgcagtcagatcctagcg
tcgagccccctctgagtcaggaaacattttcagacctatggaaactacttcctgaaaacaacgttc
tgtcccccttgccgtcccaagcaatggatgatttgatgctgtccccggacgatattgaacaatggt
tcactgaagacccaggtccagatgaagctcccagaatgccagaggctgctccccccgtgggatcca
cacgataccaagccgaggtgagacccaaagaaagctggaaccatgctgactttgtacactgtgagg
acacagagtctgttcctggaaagcccagtgtcaacgcagatgaggaagtcggaggtccccaaatct
gccgtgtatgtggggacaaggccactggctatcacttcaatgtcatgacatgtgaaggatgcaagg
gctttttcaggagggccatgaaacgcaacgcccggctgaggtgccccttccggaagggcgcctgcg
agatcacccggaagacccggcgacagtgccaggcctgccgcctgcgcaagtgcctggagagcggca
tgaagaaggagatgatcatgtccgacgaggccgtggaggagaggcgggccttgatcaagcggaaga
aaagtgaacggacagggactcagccactgggagtgcaggggctgacagaggagcagcggatgatga
tcagggagctgatggacgctcagatgaaaacctttgacactaccttctcccatttcaagaatttcc
ggctgccaggggtgcttagcagtggctgcgagttgccagagtctctgcaggccccatcgagggaag
aagctgccaagtggagccaggtccggaaagatctgtgctctttgaaggtctctctgcagctgcggg
gggaggatggcagtgtctggaactacaaacccccagccgacagtggcgggaaagagatcttctccc
tgctgccccacatggctgacatgtcaacctacatgttcaaaggcatcatcagctttgccaaagtca
tctcctacttcagggacttgcccatcgaggaccagatctccctgctgaagggggccgctttcgagc
tgtgtcaactgagattcaacacagtgttcaacgcggagactggaacctgggagtgtggccggctgt
cctactgcttggaagacactgcaggtggcttccagcaacttctactggagcccatgctgaaattcc
actacatgctgaagaagctgcagctgcatgaggaggagtatgtgctgatgcaggccatctccctct
tctccccagaccgcccaggtgtgctgcagcaccgcgtggtggaccagctgcaggagcaattcgcca
ttactctgaagtcctacattgaatgcaatcggccccagcctgctcataggttcttgttcctgaaga
tcatggctatgctcaccgagctccgcagcatcaatgctcagcacacccagcggctgctgcgcatcc
aggacatacacccctttgctacgcccctcatgcaggagttgttcggcatcacaggtagctgagaat
tcacgcgtggtacctctagagtcgacccgggcggccgcttccctttagtgagggttaatgcttcga
gcagacatgataagatacattgatgagtttggacaaaccacaactagaatgcagtgaaaaaaatgc
tttatttgtgaaatttgtgatgctattgctttatttgtaaccattataagctgcaataaacaagtt
aacaacaacaattgcattcattttatgtttcaggttcagggggagatgtgggaggttttttaaagc
aagtaaaacctctacaaatgtggtaaaatccgataaggatcgatccgggctggcgtaatagcgaag
aggcccgcaccgatcgcccttcccaacagttgcgcagcctgaatggcgaatggacgcgccctgtag
cggcgcattaagcgcggcgggtgtggtggttacgcgcagcgtgaccgctacacttgccagcgccct
agcgcccgctcctttcgctttcttcccttcctttctcgccacgttcgccggctttccccgtcaagc
tctaaatcgggggctccctttagggttccgatttagtgctttacggcacctcgaccccaaaaaact
tgattagggtgatggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgtt
ggagtccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatctcggt
ctattcttttgatttataagggattttgccgatttcggcctattggttaaaaaatgagctgattta
acaaaaatttaacgcgaattttaacaaaatattaacgcttacaatttcctgatgcggtattttctc
cttacgcatctgtgcggtatttcacaccgcatacgcggatctgcgcagcaccatggcctgaaataa
cctctgaaagaggaacttggttaggtaccttctgaggcggaaagaaccagctgtggaatgtgtgtc
agttagggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaatt
agtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagtatgcaaagcatgcatc
tcaattagtcagcaaccatagtcccgcccctaactccgcccatcccgcccctaactccgcccagtt
ccgcccattctccgccccatggctgactaattttttttatttatgcagaggccgaggccgcctcgg
cctctgagctattccagaagtagtgaggaggcttttttggaggcctaggcttttgcaaaaagcttg
attcttctgacacaacagtctcgaacttaaggctagagccaccatgattgaacaagatggattgca
cgcaggttctccggccgcttgggtggagaggctattcggctatgactgggcacaacagacaatcgg
ctgctctgatgccgccgtgttccggctgtcagcgcaggggcgcccggttctttttgtcaagaccga
cctgtccggtgccctgaatgaactgcaggacgaggcagcgcggctatcgtggctggccacgacggg
cgttccttgcgcagctgtgctcgacgttgtcactgaagcgggaagggactggctgctattgggcga
agtgccggggcaggatctcctgtcatctcaccttgctcctgccgagaaagtatccatcatggctga
tgcaatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcgaaacatcg
catcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggatgatctggacgaagagca
tcaggggctcgcgccagccgaactgttcgccaggctcaaggcgcgcatgcccgacggcgaggatct
cgtcgtgacccatggcgatgcctgcttgccgaatatcatggtggaaaatggccgcttttctggatt
catcgactgtggccggctgggtgtggcggaccgctatcaggacatagcgttggctacccgtgatat
tgctgaagagcttggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccga
ttcgcagcgcatcgccttctatcgccttcttgacgagttcttctgagcgggactctggggttcgaa
atgaccgaccaagcgacgcccaacctgccatcacgatggccgcaataaaatatctttattttcatt
acatctgtgtgttggttttttgtgtgaatcgatagcgataaggatccgcgtatggtgcactctcag
tacaatctgctctgatgccgcatagttaagccagccccgacacccgccaacacccgctgacgcgcc
ctgacgggcttgtctgctcccggcatccgcttacagacaagctgtgaccgtctccgggagctgcat
gtgtcagaggttttcaccgtcatcaccgaaacgcgcgagacgaaagggcctcgtgatacgcctatt
tttataggttaatgtcatgataataatggtttcttagacgtcaggtggcacttttcggggaaatgt
gcgcggaacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgagacaata
accctgataaatgcttcaataatattgaaaaaggaagagtatgagtattcaacatttccgtgtcgc
ccttattcccttttttgcggcattttgccttcctgtttttgctcacccagaaacgctggtgaaagt
aaaagatgctgaagatcagttgggtgcacgagtgggttacatcgaactggatctcaacagcggtaa
gatccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaaagttctgctatg
tggcgcggtattatcccgtattgacgccgggcaagagcaactcggtcgccgcatacactattctca
gaatgacttggttgagtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagaga
attatgcagtgctgccataaccatgagtgataacactgcggccaacttacttctgacaacgatcgg
aggaccgaaggagctaaccgcttttttgcacaacatgggggatcatgtaactcgccttgatcgttg
ggaaccggagctgaatgaagccataccaaacgacgagcgtgacaccacgatgcctgtagcaatggc
aacaacgttgcgcaaactattaactggcgaactacttactctagcttcccggcaacaattaataga
ctggatggaggcggataaagttgcaggaccacttctgcgctcggcccttccggctggctggtttat
tgctgataaatctggagccggtgagcgtgggtctcgcggtatcattgcagcactggggccagatgg
taagccctcccgtatcgtagttatctacacgacggggagtcaggcaactatggatgaacgaaatag
acagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactcata
tatactttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatcctttttga
taatctcatgaccaaaatcccttaacgtgagttttcgttccactgagcgtcagaccccgtagaaaa
gatcaaaggatcttcttgagatcctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaacc
accgctaccagcggtggtttgtttgccggatcaagagctaccaactctttttccgaaggtaactgg
cttcagcagagcgcagataccaaatactgttcttctagtgtagccgtagttaggccaccacttcaa
gaactctgtagcaccgcctacatacctcgctctgctaatcctgttaccagtggctgctgccagtgg
cgataagtcgtgtcttaccgggttggactcaagacgatagttaccggataaggcgcagcggtcggg
ctgaacggggggttcgtgcacacagcccagcttggagcgaacgacctacaccgaactgagatacct
acagcgtgagctatgagaaagcgccacgcttcccgaagggagaaaggcggacaggtatccggtaag
cggcagggtcggaacaggagagcgcacgagggagcttccagggggaaacgcctggtatctttatag
tcctgtcgggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcaggggggcggag
cctatggaaaaacgccagcaacgcggcctttttacggttcctggccttttgctggccttttgctca
catggctcgacagatct
<210>4
<211>676
<212>PRT
<213> artificial sequence
<220>
<221>PCI-P53-hPXR
<223>143-215 is P53,216-222 be linker, 223-655 is hPXR.
<400>4
Arg Pro Val Asp Ala Asn Gly Arg Xaa Ala Cys Thr Val Gly Gly Leu
5 10 15
Tyr Lys Gln Ser Ser Phe Ser Glu Pro Ser Asp His Xaa Lys Leu Tyr
20 25 30
Cys Gly Ser Leu Ser Gln Leu Asn Cys Xaa Arg Ser Gln Cys Phe Xaa
35 40 45
His Asn Ser Leu Glu Leu Lys Leu Gln Xaa Leu Ser Xaa Gly Ser Leu
50 55 60
Ala Glu Val Gly Arg Glu Ala Leu Gly Arg Xaa Val Ser Arg Leu Gln
65 70 75 80
Asp Arg Phe Lys Glu Thr Asn Arg Asn Trp Ala Cys Arg Asp Arg Glu
85 90 95
Asp Ser Cys Val Ser Asp Arg His Leu Leu Val Leu Leu Thr Ser Thr
100 105 110
Leu Pro Phe Ser Pro Gln Val Ser Thr Pro Ser Ser Ile Thr Ala Leu
115 120 125
Lys Ala Arg Val Leu Asn Thr Thr His Tyr Arg Leu Ala Thr Met Glu
130 135 140
Glu Pro Gln Ser Asp Pro Ser Val Glu Pro Pro Leu Ser Gln Glu Thr
145 150 155 160
Phe Ser Asp Leu Trp Lys Leu Leu Pro Glu Asn Asn Val Leu Ser Pro
165 170 175
Leu Pro Ser Gln Ala Met Asp Asp Leu Met Leu Ser Pro Asp Asp Ile
180 185 190
Glu Gln Trp Phe Thr Glu Asp Pro Gly Pro Asp Glu Ala Pro Arg Met
195 200 205
Pro Glu Ala Ala Pro Pro Val Gly Ser Thr Arg Tyr Gln Ala Glu Val
210 215 220
Arg Pro Lys Glu Ser Trp Asn His Ala Asp Phe Val His Cys Glu Asp
225 230 235 240
Thr Glu Ser Val Pro Gly Lys Pro Ser Val Asn Ala Asp Glu Glu Val
245 250 255
Gly Gly Pro Gln Ile Cys Arg Val Cys Gly Asp Lys Ala Thr Gly Tyr
260 265 270
His Phe Asn Val Met Thr Cys Glu Gly Cys Lys Gly Phe Phe Arg Arg
275 280 285
Ala Met Lys Arg Asn Ala Arg Leu Arg Cys Pro Phe Arg Lys Gly Ala
290 295 300
Cys Glu Ile Thr Arg Lys Thr Arg Arg Gln Cys Gln Ala Cys Arg Leu
305 310 315 320
Arg Lys Cys Leu Glu Ser Gly Met Lys Lys Glu Met Ile Met Ser Asp
325 330 335
Glu Ala Val Glu Glu Arg Arg Ala Leu Ile Lys Arg Lys Lys Ser Glu
340 345 350
Arg Thr Gly Thr Gln Pro Leu Gly Val Gln Gly Leu Thr Glu Glu Gln
355 360 365
Arg Met Met Ile Arg Glu Leu Met Asp Ala Gln Met Lys Thr Phe Asp
370 375 380
Thr Thr Phe Ser His Phe Lys Asn Phe Arg Leu Pro Gly Val Leu Ser
385 390 395 400
Ser Gly Cys Glu Leu Pro Glu Ser Leu Gln Ala Pro Ser Arg Glu Glu
405 410 415
Ala Ala Lys Trp Ser Gln Val Arg Lys Asp Leu Cys Ser Leu Lys Val
420 425 430
Ser Leu Gln Leu Arg Gly Glu Asp Gly Ser Val Trp Asn Tyr Lys Pro
435 440 445
Pro Ala Asp Ser Gly Gly Lys Glu Ile Phe Ser Leu Leu Pro His Met
450 455 460
Ala Asp Met Ser Thr Tyr Met Phe Lys Gly Ile Ile Ser Phe Ala Lys
465 470 475 480
Val Ile Ser Tyr Phe Arg Asp Leu Pro Ile Glu Asp Gln Ile Ser Leu
485 490 495
Leu Lys Gly Ala Ala Phe Glu Leu Cys Gln Leu Arg Phe Asn Thr Val
500 505 510
Phe Asn Ala Glu Thr Gly Thr Trp Glu Cys Gly Arg Leu Ser Tyr Cys
515 520 525
Leu Glu Asp Thr Ala Gly Gly Phe Gln Gln Leu Leu Leu Glu Pro Met
530 535 540
Leu Lys Phe His Tyr Met Leu Lys Lys Leu Gln Leu His Glu Glu Glu
545 550 555 560
Tyr Val Leu Met Gln Ala Ile Ser Leu Phe Ser Pro Asp Arg Pro Gly
565 570 575
Val Leu Gln His Arg Val Val Asp Gln Leu Gln Glu Gln Phe Ala Ile
580 585 590
Thr Leu Lys Ser Tyr Ile Glu Cys Asn Arg Pro Gln Pro Ala His Arg
595 600 605
Phe Leu Phe Leu Lys Ile Met Ala Met Leu Thr Glu Leu Arg Ser Ile
610 615 620
Asn Ala Gln His Thr Gln Arg Leu Leu Arg Ile Gln Asp Ile His His
625 630 635 640
Pro Phe Ala Thr Pro Leu Met Gln Glu Leu Phe Gly Ile Thr Gly Ser
645 650 655
Xaa Glu Phe Thr Arg Gly Thr Ser Arg Val Asp Pro Gly Gly Arg Phe
660 665 670
Pro Leu Val Arg
675
<210>5
<211>5472
<212>DNA
<213>PCI-neo Vector
<400>5
tcaatattggccattagccatattattcattggttatatagcataaatcaatattggctattggcc
attgcatacgttgtatctatatcataatatgtacatttatattggctcatgtccaatatgaccgcc
atgttggcattgattattgactagttattaatagtaatcaattacggggtcattagttcatagccc
atatatggagttccgcgttacataacttacggtaaatggcccgcctggctgaccgcccaacgaccc
ccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaatagggactttccattgacg
tcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaag
tccgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgacctt
acgggactttcctacttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggtt
ttggcagtacaccaatgggcgtggatagcggtttgactcacggggatttccaagtctccaccccat
tgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgtcgtaacaactg
cgatcgcccgccccgttgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcaga
gctcgtttagtgaaccgtcagatcactagaagctttattgcggtagtttatcacagttaaattgct
aacgcagtcagtgcttctgacacaacagtctcgaacttaagctgcagtgactctcttaaggtagcc
ttgcagaagttggtcgtgaggcactgggcaggtaagtatcaaggttacaagacaggtttaaggaga
ccaatagaaactgggcttgtcgagacagagaagactcttgcgtttctgataggcacctattggtct
tactgacatccactttgcctttctctccacaggtgtccactcccagttcaattacagctcttaagg
ctagagtacttaatacgactcactataggctagcctcgagaattcacgcgtggtacctctagagtc
gacccgggcggccgcttccctttagtgagggttaatgcttcgagcagacatgataagatacattga
tgagtttggacaaaccacaactagaatgcagtgaaaaaaatgctttatttgtgaaatttgtgatgc
tattgctttatttgtaaccattataagctgcaataaacaagttaacaacaacaattgcattcattt
tatgtttcaggttcagggggagatgtgggaggttttttaaagcaagtaaaacctctacaaatgtgg
taaaatccgataaggatcgatccgggctggcgtaatagcgaagaggcccgcaccgatcgcccttcc
caacagttgcgcagcctgaatggcgaatggacgcgccctgtagcggcgcattaagcgcggcgggtg
tggtggttacgcgcagcgtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttct
tcccttcctttctcgccacgttcgccggctttccccgtcaagctctaaatcgggggctccctttag
ggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgatggttcacgta
gtgggccatcgccctgatagacggtttttcgccctttgacgttggagtccacgttctttaatagtg
gactcttgttccaaactggaacaacactcaaccctatctcggtctattcttttgatttataaggga
ttttgccgatttcggcctattggttaaaaaatgagctgatttaacaaaaatttaacgcgaatttta
acaaaatattaacgcttacaatttcctgatgcggtattttctccttacgcatctgtgcggtatttc
acaccgcatacgcggatctgcgcagcaccatggcctgaaataacctctgaaagaggaacttggtta
ggtaccttctgaggcggaaagaaccagctgtggaatgtgtgtcagttagggtgtggaaagtcccca
ggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccaggtgtggaaag
tccccaggctccccagcaggcagaagtatgcaaagcatgcatctcaattagtcagcaaccatagtc
ccgcccctaactccgcccatcccgcccctaactccgcccagttccgcccattctccgccccatggc
tgactaattttttttatttatgcagaggccgaggccgcctcggcctctgagctattccagaagtag
tgaggaggcttttttggaggcctaggcttttgcaaaaagcttgattcttctgacacaacagtctcg
aacttaaggctagagccaccatgattgaacaagatggattgcacgcaggttctccggccgcttggg
tggagaggctattcggctatgactgggcacaacagacaatcggctgctctgatgccgccgtgttcc
ggctgtcagcgcaggggcgcccggttctttttgtcaagaccgacctgtccggtgccctgaatgaac
tgcaggacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtgctcg
acgttgtcactgaagcgggaagggactggctgctattgggcgaagtgccggggcaggatctcctgt
catctcaccttgctcctgccgagaaagtatccatcatggctgatgcaatgcggcggctgcatacgc
ttgatccggctacctgcccattcgaccaccaagcgaaacatcgcatcgagcgagcacgtactcgga
tggaagccggtcttgtcgatcaggatgatctggacgaagagcatcaggggctcgcgccagccgaac
tgttcgccaggctcaaggcgcgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcct
gcttgccgaatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggtg
tggcggaccgctatcaggacatagcgttggctacccgtgatattgctgaagagcttggcggcgaat
gggctgaccgcttcctcgtgctttacggtatcgccgctcccgattcgcagcgcatcgccttctatc
gccttcttgacgagttcttctgagcgggactctggggttcgaaatgaccgaccaagcgacgcccaa
cctgccatcacgatggccgcaataaaatatctttattttcattacatctgtgtgttggttttttgt
gtgaatcgatagcgataaggatccgcgtatggtgcactctcagtacaatctgctctgatgccgcat
agttaagccagccccgacacccgccaacacccgctgacgcgccctgacgggcttgtctgctcccgg
catccgcttacagacaagctgtgaccgtctccgggagctgcatgtgtcagaggttttcaccgtcat
caccgaaacgcgcgagacgaaagggcctcgtgatacgcctatttttataggttaatgtcatgataa
taatggtttcttagacgtcaggtggcacttttcggggaaatgtgcgcggaacccctatttgtttat
ttttctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataat
attgaaaaaggaagagtatgagtattcaacatttccgtgtcgcccttattcccttttttgcggcat
tttgccttcctgtttttgctcacccagaaacgctggtgaaagtaaaagatgctgaagatcagttgg
gtgcacgagtgggttacatcgaactggatctcaacagcggtaagatccttgagagttttcgccccg
aagaacgttttccaatgatgagcacttttaaagttctgctatgtggcgcggtattatcccgtattg
acgccgggcaagagcaactcggtcgccgcatacactattctcagaatgacttggttgagtactcac
cagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataacca
tgagtgataacactgcggccaacttacttctgacaacgatcggaggaccgaaggagctaaccgctt
ttttgcacaacatgggggatcatgtaactcgccttgatcgttgggaaccggagctgaatgaagcca
taccaaacgacgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaaactattaa
ctggcgaactacttactctagcttcccggcaacaattaatagactggatggaggcggataaagttg
caggaccacttctgcgctcggcccttccggctggctggtttattgctgataaatctggagccggtg
agcgtgggtctcgcggtatcattgcagcactggggccagatggtaagccctcccgtatcgtagtta
tctacacgacggggagtcaggcaactatggatgaacgaaatagacagatcgctgagataggtgcct
cactgattaagcattggtaactgtcagaccaagtttactcatatatactttagattgatttaaaac
ttcatttttaatttaaaaggatctaggtgaagatcctttttgataatctcatgaccaaaatccctt
aacgtgagttttcgttccactgagcgtcagaccccgtagaaaagatcaaaggatcttcttgagatc
ctttttttctgcgcgtaatctgctgcttgcaaacaaaaaaaccaccgctaccagcggtggtttgtt
tgccggatcaagagctaccaactctttttccgaaggtaactggcttcagcagagcgcagataccaa
atactgttcttctagtgtagccgtagttaggccaccacttcaagaactctgtagcaccgcctacat
acctcgctctgctaatcctgttaccagtggctgctgccagtggcgataagtcgtgtcttaccgggt
tggactcaagacgatagttaccggataaggcgcagcggtcgggctgaacggggggttcgtgcacac
agcccagcttggagcgaacgacctacaccgaactgagatacctacagcgtgagctatgagaaagcg
ccacgcttcccgaagggagaaaggcggacaggtatccggtaagcggcagggtcggaacaggagagc
gcacgagggagcttccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccacctct
gacttgagcgtcgatttttgtgatgctcgtcaggggggcggagcctatggaaaaacgccagcaacg
cggcctttttacggttcctggccttttgctggccttttgctcacatggctcgacagatct
Claims (9)
1., for improving the mosaic gene that the hepatocellular physiological CYP3A4 of vitro culture of human expresses, it is characterized in that: its sequence is for shown in SEQ ID No.1 or SEQ ID No.3.
2. a recombinant eukaryon expression vector, is characterized in that, it comprises mosaic gene as claimed in claim 1.
3. recombinant eukaryon expression vector as claimed in claim 2, is characterized in that: described carrier for expression of eukaryon is mammalian cell expression vector.
4. recombinant eukaryon expression vector as claimed in claim 3, is characterized in that: described mammalian cell expression vector is PCI-neo mammalian expression vector.
5. recombinant eukaryon expression vector as claimed in claim 4, is characterized in that: described PCI-neo mammalian expression vector comprises β-globin/IgG chimeric intron sequence successively and SV40Late poly (A) signal sequence in the early stage enhancers/promoters sequence of human cytomegalovirus and downstream thereof.
6. recombinant eukaryon expression vector as claimed in claim 5, is characterized in that: comprise following restriction enzyme site between the β-globin/IgG chimeric intron sequence of described PCI-neo mammalian expression vector and SV40Late poly (A) signal sequence: Nhe I, Xho I, EcoR I, Mlu I, Xba I, Sal I, Acc I, Sma I and Not I.
7. a construction process for the recombinant eukaryon expression vector as described in claim 2-6 any one, is characterized in that, it comprises the following steps:
(1) the cDNA human cloning nf Pregnane X Receptor full length gene sequence that normal people's primary hepatocyte of including according to GenBank database is originated;
(2) the activation domain sequence of the cDNA sequence clone wild-type P53 gene of including according to GenBank database;
(3) two sections of sequence construct orderings that described step (1) and (2) obtain are classified as the mosaic gene shown in SEQ ID No.1 or SEQ ID No.3, and between directed cloning to the β-globin/IgG chimeric intron sequence and SV40Late poly (A) signal sequence of PCI-neo mammalian expression vector, obtain recombinant eukaryon expression vector.
8. the construction process of recombinant eukaryon expression vector as claimed in claim 7, is characterized in that: the activation domain sequence orientation of described people's nf Pregnane X Receptor full length gene sequence and wild type P53 gene is inserted on Nhe I, the Xho I of described PCI-neo mammalian expression vector, EcoR I, Mlu I, Xba I, Sal I, Acc I, Sma I and any one restriction enzyme site of Not I.
9. the construction process of recombinant eukaryon expression vector as claimed in claim 7, is characterized in that: the recombinant eukaryon expression vector of described acquisition is by restriction map method and/or measure its nucleotide sequence and carry out screening and identification.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310282063.6A CN103421831B (en) | 2013-07-05 | 2013-07-05 | For improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310282063.6A CN103421831B (en) | 2013-07-05 | 2013-07-05 | For improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103421831A CN103421831A (en) | 2013-12-04 |
CN103421831B true CN103421831B (en) | 2015-09-16 |
Family
ID=49647223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310282063.6A Active CN103421831B (en) | 2013-07-05 | 2013-07-05 | For improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103421831B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107964534A (en) * | 2016-10-19 | 2018-04-27 | 北京大学 | The method for transforming artificial liver seed cell |
-
2013
- 2013-07-05 CN CN201310282063.6A patent/CN103421831B/en active Active
Non-Patent Citations (5)
Title |
---|
Determinants of Specificity of MDM2 for the Activation Domains of p53 and p65: Proline27 Disrupts the MDM2-Binding Motif of p53;Susan Carr Zondlo等;《Biochemistry》;20060907;第45卷;11945-11957 * |
Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors;Jenni Küblbeck等;《 European Journal of Pharmaceutical Sciences》;20100408;第40卷;263-272 * |
孕烷X受体的研究进展;梁海伟 等;《生物技术通讯》;20130531;第24卷(第3期);441-445 * |
突变p53 功能研究新进展与个性化的肿瘤治疗新策略;陆思千 等;《遗传》;20110630;第33卷(第6期);539-548 * |
转录因子CCAAT 增强子结合蛋白β(C/EBP β)的研究;高运臻 等;《遗传》;20110331;第33卷(第3期);198-206 * |
Also Published As
Publication number | Publication date |
---|---|
CN103421831A (en) | 2013-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dunn et al. | Neural crest-directed gene transfer demonstrates Wnt1 role in melanocyte expansion and differentiation during mouse development | |
Gross et al. | Spying on cancer: molecular imaging in vivo with genetically encoded reporters | |
CN102803508B (en) | For composition and the method for stem cell imaging | |
CN103298938B (en) | Oxidative stress indicator is expressed with nucleic acid construct thing and application thereof | |
Gao et al. | F2L, a peptide derived from heme-binding protein, chemoattracts mouse neutrophils by specifically activating Fpr2, the low-affinity N-formylpeptide receptor | |
CN113544273A (en) | Synthetic molecular feedback loop and method of use thereof | |
Fumagalli et al. | Group 1 ILCs regulate T cell–mediated liver immunopathology by controlling local IL-2 availability | |
CN101041816B (en) | Artificial antigen presenting cell and preparation method thereof | |
Peng et al. | A simple, rapid method for evaluation of transfection efficiency based on fluorescent dye | |
Cron et al. | Consistent transient transfection of DNA into non-transformed human and murine T-lymphocytes | |
CN103421831B (en) | For improving mosaic gene and the construction process thereof of the hepatocellular physiological CYP3A4 expression of vitro culture of human | |
Fischer et al. | Cyclic derivatives of the chemerin C-terminus as metabolically stable agonists at the chemokine-like receptor 1 for cancer treatment | |
Grady et al. | A putative design for the electromagnetic activation of split proteins for molecular and cellular manipulation | |
US20130031644A1 (en) | Autonomous lux reporter system and methods of use | |
EP3196303B1 (en) | Inflammation reporter system | |
CN105177023B (en) | Photosensitive degradant desVVD with stability regulated by blue light in eukaryotic cell | |
CN109970849A (en) | The application of zkscan3 gene or its protein inhibitor in oncotherapy | |
Sorrentino et al. | In vivo applications of chemogenetics in redox (patho) biology | |
CN102978202A (en) | Over-expression vector for muscle specific expression of pig IGF1 gene | |
JP6099075B2 (en) | Method for promoting transport of target mRNA from nucleus to cytoplasm, protein expression method and production method, and kit used therefor | |
Lin et al. | AgRP Neuron-Specific Ablation Represses Appetite, Energy Intake, and Somatic Growth in Larval Zebrafish | |
US20230392158A1 (en) | Controlling cellular behavior using feed-forward circuits | |
Surzyn et al. | IL-10 secretion increases signal persistence of HEMA-MMA–microencapsulated luciferase-modified CHO fibroblasts in mice | |
Du et al. | Bioluminescence imaging of hepatitis B virus enhancer and promoter activities in mice | |
Awais et al. | An efficient method is required to transfect non-dividing cells with genetically encoded optical probes for molecular imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |